Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ciclopirox nail lacquer topical solution 8%.

A K Gupta1

  • 1Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.

Skin Therapy Letter
|October 12, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peripheral edema due to nifedipine-itraconazole interaction: a case report.

Archives of dermatology·1996
Same author

High frequency 40-MHz ultrasound. A possible noninvasive method for the assessment of the boundary of basal cell carcinomas.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·1996
Same author

Effect of ionizing radiation on AP-1 binding activity and basic fibroblast growth factor gene expression in drug-sensitive human breast carcinoma MCF-7 and multidrug-resistant MCF-7/ADR cells.

The Journal of biological chemistry·1995
Same author

Role of cellular casein kinase II in the function of the phosphoprotein (P) subunit of RNA polymerase of vesicular stomatitis virus.

The Journal of biological chemistry·1995
Same author

Fundus imaging in patients with cataract: role for a variable wavelength scanning laser ophthalmoscope.

The British journal of ophthalmology·1995
Same author

Age and gender differences in the impact of psoriasis on quality of life.

International journal of dermatology·1995

Ciclopirox nail lacquer 8% is approved for mild to moderate fingernail and toenail fungus in immunocompetent patients. It is used alongside professional nail removal as part of a comprehensive treatment plan.

Area of Science:

  • Dermatology
  • Mycology
  • Pharmacology

Background:

  • Onychomycosis, a fungal nail infection, affects millions globally.
  • Treatment options for onychomycosis are limited, especially for mild to moderate cases.
  • Topical antifungal therapies are often used as part of a comprehensive management program.

Purpose of the Study:

  • To review the approval and recommended use of Ciclopirox nail lacquer 8% for onychomycosis.
  • To highlight the importance of a comprehensive management program in conjunction with topical therapy.
  • To inform healthcare professionals and patients about the indications and limitations of Ciclopirox nail lacquer.

Main Methods:

  • Review of US FDA approval documentation.
  • Analysis of the components of the comprehensive management program.

Related Experiment Videos

  • Identification of patient population and nail involvement criteria.

    • Main Results:

    • Ciclopirox nail lacquer 8% (Penlac) approved by US FDA in December 1999.
    • Indicated for mild to moderate fingernail and toenail onychomycosis caused by Trichophyton rubrum.
    • Requires use in immunocompetent patients without lunula involvement.
    • Part of a comprehensive management program including professional nail removal.

    Conclusions:

    • Ciclopirox nail lacquer 8% is an approved treatment for specific onychomycosis cases.
    • Effective management requires a combination of topical lacquers and professional nail care.
    • The treatment is not approved for use in Canada.